APEX2

Across TCGA pan-cancer cohorts, APEX2 RNA is linked to patient survival in 28 of 34 cancer types, making it the most broadly survival-associated APEX2 data layer compared with 6 for mutation status and 3 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher APEX2 RNA is associated with better overall survival. In most high-consensus cancer types, elevated APEX2 expression acts as an unfavorable survival marker, although some lineages such as OV and SCLC show a favorable association.

OV, SCLC, and LIHC are the cancer types where APEX2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Tertile	IV	0.580	0.211	<.001	110	view →
SCLC	OS	Tertile	III,IV	0.742	0.258	<.001	94	view →
LIHC	OS	Median	All	0.598	0.770	<.001	88	view →
KIRP	OS	Median	All	0.533	0.922	<.001	55	view →
LGG	OS	Median	All	0.749	0.873	<.001	51	view →
KICH	OS	Quartile	All	0.563	1.000	.008	48	view →
PAAD	DFS	Median	All	0.212	0.494	<.001	38	view →
LAML	DFS	Quartile	All	0.451	0.709	.004	38	view →
LUAD	DFS	Median	All	0.614	0.713	.009	37	view →
CESC	OS	Quartile	All	0.969	0.820	<.001	36	view →
KIRC	DFS	Median	All	0.730	0.502	.004	18	view →
SARC	DFS	Median	All	0.552	0.667	.009	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 28 lineages.

APEX2–OV (OS)

Open the OV breakdown →